NZ585438A - Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide - Google Patents

Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide

Info

Publication number
NZ585438A
NZ585438A NZ585438A NZ58543808A NZ585438A NZ 585438 A NZ585438 A NZ 585438A NZ 585438 A NZ585438 A NZ 585438A NZ 58543808 A NZ58543808 A NZ 58543808A NZ 585438 A NZ585438 A NZ 585438A
Authority
NZ
New Zealand
Prior art keywords
methoxyphenoxy
benzenesulfonamide
hydroxyethoxy
pyrimidin
pyrimidinyl
Prior art date
Application number
NZ585438A
Other languages
English (en)
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Mekde
Prakash Bansode
Dattatraya Shinde
Sunanda Phadtare
Original Assignee
Generics Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics Uk Ltd filed Critical Generics Uk Ltd
Priority to NZ600010A priority Critical patent/NZ600010A/xx
Publication of NZ585438A publication Critical patent/NZ585438A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ585438A 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide NZ585438A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2108MU2007 2007-10-24
PCT/GB2008/050986 WO2009053748A2 (en) 2007-10-24 2008-10-24 Novel crystalline forms

Publications (1)

Publication Number Publication Date
NZ585438A true NZ585438A (en) 2012-09-28

Family

ID=40262729

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ585438A NZ585438A (en) 2007-10-24 2008-10-24 Novel crystalline forms of 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-pyrimidin-4-yI]-benzenesulfonamide
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ600010A NZ600010A (en) 2007-10-24 2008-10-24 Novel crystalline forms of bosentan, processes for their preparation and uses thereof

Country Status (8)

Country Link
US (1) US8530488B2 (enExample)
EP (1) EP2222649A2 (enExample)
JP (1) JP2011500780A (enExample)
CN (1) CN101939303B (enExample)
AU (1) AU2008315757A1 (enExample)
CA (1) CA2703230A1 (enExample)
NZ (2) NZ585438A (enExample)
WO (1) WO2009053748A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008135795A2 (en) * 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) * 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
AU2009203174B2 (en) * 2008-01-01 2014-01-30 Cipla Limited Method of synthesis of bosentan, its polymorphic forms and its salts
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
US20110263623A1 (en) 2008-08-12 2011-10-27 Cadila Healthcare Limited Process for preparation of bosentan
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
PL402305A1 (pl) * 2012-12-30 2014-07-07 Instytut Farmaceutyczny Sposób wytwarzania bozentanu w postaci monohydratu o czystości farmaceutycznej

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570699B1 (fr) * 1984-09-24 1987-08-28 Roussel Uclaf Nouveau procede de preparation de derives du 4h-1,2,4-triazole, nouveaux triazoles ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5276004A (en) * 1987-03-20 1994-01-04 Dai Nippon Insatsu Kabushiki Kaisha Process for heat transfer recording
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
SI1535613T1 (sl) 1999-11-17 2010-12-31 Teva Pharma Postopek za pripravo polimorfne oblike atorvastatin kalcija
HUP0204069A3 (en) 1999-12-16 2005-01-28 Teva Pharma Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
PT1254121E (pt) * 2000-01-25 2006-06-30 Hoffmann La Roche Preparacao de sulfonamidas
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
AU2003209669A1 (en) 2003-02-25 2004-09-17 Hetero Drugs Limited Amorphous form of losartan potassium
US7872019B2 (en) 2003-03-12 2011-01-18 Cadila Healthcare Limited Polymorphs and amorphous form of (S)-(+)-clopidogrel bisulfate
WO2004087660A1 (en) 2003-04-02 2004-10-14 Hetero Drugs Limited A novel process for amorphous form of donepezil hydrochloride
US20080188663A1 (en) * 2007-01-29 2008-08-07 Ashok Kumar Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I
BRPI0809171A2 (pt) * 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
WO2008135795A2 (en) 2007-05-08 2008-11-13 Generics [Uk] Limited Polymorphic forms of bosentan
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
EP2205591A1 (en) 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
US8530488B2 (en) * 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
ATE530531T1 (de) 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
WO2009095933A2 (en) 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
WO2009112954A2 (en) 2008-03-13 2009-09-17 Actavis Group Ptc Ehf Processes for the preparation of bosentan and related compounds using novel intermediates
WO2009141167A1 (en) 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
JP2012507497A (ja) 2008-11-03 2012-03-29 ジェネリクス・（ユーケー）・リミテッド ボセンタンおよび関連物質のｈｐｌｃ分析方法、ならびに参照スタンダードまたはマーカーとしてのこれら物質の使用
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan

Also Published As

Publication number Publication date
EP2222649A2 (en) 2010-09-01
AU2008315757A1 (en) 2009-04-30
CN101939303B (zh) 2014-06-11
WO2009053748A3 (en) 2009-06-18
US8530488B2 (en) 2013-09-10
NZ600010A (en) 2013-11-29
US20100331352A1 (en) 2010-12-30
CN101939303A (zh) 2011-01-05
WO2009053748A2 (en) 2009-04-30
CA2703230A1 (en) 2009-04-30
JP2011500780A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
NZ600010A (en) Novel crystalline forms of bosentan, processes for their preparation and uses thereof
PL1883397T3 (pl) Dyspergowalna tabletka bosertanu
Ludovici et al. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues
NZ700778A (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methyl-urea and salts thereof.
WO2004046118A3 (en) 2-4-(di-phenyl-amino)-pyrimidine derivatives useful for treating hyper-proliferative disorders
CN101914065A (zh) 有助于治疗由crth2介导的疾病的嘧啶衍生物
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
DK1891019T3 (da) 2,6-substituerede, 4-monosubstituerede aminopyrimidiner som prostaglandin-D2-receptorantagonister
MX2022013804A (es) Polimorfos de moduladores de los receptores de pirimidin-ciclohexil-glucocorticoides.
WO2009080721A3 (en) 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists
WO2007027238A3 (en) Jak kinase inhibitors and their uses
MXPA05011643A (es) 5,7-diaminopirazolo[4,3-d]pirimidinas en el tratamiento de hipertension.
EP2072503A3 (en) Process for the preparation of bosentan
WO2009157014A3 (en) A process for preparing hmg-coa reductase inhibitors and intermediates
MX2010007392A (es) Antagonistas de trpa1.
ATE133944T1 (de) Substituierte aminopyrimidine als angiotensin ii antagonisten
EP4275755A3 (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
TN2010000070A1 (en) Fused bicyclic pyrimidines
MX2007015427A (es) Inhibidores de azinona y diazinona v3 para depresion y trastornos de estres.
SG10201902903RA (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2006135839A3 (en) Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
EP2769721A3 (en) Process for the preparation of substituted pyrimidine derivatives
NZ593117A (en) HPLC METHOD FOR THE ANALYSIS OF BOSENTAN AND RELATED SUBSTANCES AND USE OF THESE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS Chromatography mass spectrometry fragmentation
MX2010003178A (es) Primidinas sustituidas con 2-s-bencilo como antagonistas de crth2.
WO2009024323A3 (en) Process for preparing pyrimidine derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 OCT 2015 BY SPRUSON + FERGUSON

Effective date: 20130211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 OCT 2016 BY COMPUTER PACKAGES INC

Effective date: 20151001

LAPS Patent lapsed